Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

doi:10.1158/1078-0432.CCR-17-3588

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2018

Lim Ho Yeong, Merle Philippe, Weiss Karl Heinz, Yau Thomas, Ross Paul, Mazzaferro Vincenzo, Blanc Jean-Frédéric, Ma Yuk Ting, Yen Chia Jui, Kocsis Judit, Choo Su Pin, Sukeepaisarnjaroen Wattana, Gérolami René, Dufour Jean-François, Gane Edward J, Ryoo Baek-Yeol, Peck-Radosavljevic Markus, Dao Thong, Yeo Winnie, Lamlertthon Wisut, Thongsawat Satawat, Teufel Michael, Roth Katrin, Reis Diego, Childs Barrett H, Krissel Heiko, Llovet Josep M

Abstract excerpt

Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC). Two phase II studies evaluated the efficacy of refametinib monotherapy and refametinib plus sorafenib in patients with RAS-mutant unresectable or metastatic HCC.Patients and Methods: Eligible patients with RAS mutations of cell-free circulating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Disease-Free Survival

Share to MAP Kinase Kinase Kinases

Share to ras Proteins

Share to Sorafenib

Share to Sulfonamides

Share to Telomerase

Source

Open in PubMed

Identifiers

PMID: 29950351
DOI: 10.1158/1078-0432.CCR-17-3588

Genes

CTNNB1
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.PMID 29950351Read ↗

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.Semantic proximity Read ↗

Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.Semantic proximity Read ↗

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with SorafenibSemantic proximity Read ↗

Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinomaSemantic proximity Read ↗

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNASemantic proximity Read ↗

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.Semantic proximity Read ↗

Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.